New Data Demonstrate Greater Pain Relief With Boston Scientific Precision Spectra™ Spinal Cord Stimulator System

Boston Scientific Corporation

presented new data demonstrating  that the Precision Spectra™ Spinal Cord Stimulator (SCS) System provided 1.5 times better overall pain relief and 2 times better low back pain relief than the previous generation Precision Plus™ SCS system. The improved outcomes with the Precision Spectra System were achieved in conjunction with the use of the proprietary Illumina™ 3D neural targeting software, designed to target pain with point-and-click simplicity. Results from the LUMINA cohort of the Precision Spectra System observational study were presented this week at the International Neuromodulation Society 12th World Congress in Montreal, Canada. The LUMINA cohort includes three patient groups:  213 consecutive patients treated with the Precision Spectra System for up to 24 months post-implant; 130 consecutive patients treated with the previous generation system, Precision Plus™, in a comparative evaluation with the Precision Spectra System; and 25 consecutive patients treated with the Precision Spectra System and the new CoverEdge 32 Surgical Leads for up to 6 months post-implant. "The results are exciting because we looked at consecutive patients – some with only low back pain – in a real-world setting," said Julie Pilitsis, M.D., Ph.D., associate professor, Albany